Drug intelligence / Profile preview

OC-3

Development stage: Preclinical
Lead developer: OneChain Immunotherapeutics
Modality: Small Molecules

Overview

OC-3 is an investigational drug initially developed by OneChain Immunotherapeutics, currently at the discovery stage of development. There is no publicly available detailed mechanism of action, known active ingredient, or indication as of now. It is not listed as an established pharmaceutical, nor is it an abbreviation or street name for an existing approved drug. Further information on molecular targets, modality, route of administration, or disease indications is not publicly disclosed[1].

Targets

PARP1 (Poly (adp-ribose) polymerase 1)

Beyond the preview

Go deeper on OC-3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OC-3.

Explore the full profile